Flavio Falcinelli

Perugia, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Short BRAF+MEK coinhibition, alone and combined with anti-CD20 immunotherapy, in relapsed or refractory hairy cell leukemia: An investigator-sponsored multi-center phase 2 clinical trial.

Short BRAF+MEK coinhibition, alone and combined with anti-CD20 immunotherapy, in relapsed or refractory hairy cell leukemia: An investigator-sponsored multi-center phase 2 clinical trial.

Journal: HemaSphere

Published: April 30, 2026

Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial.

Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial.

Journal: HemaSphere

Published: April 02, 2026

Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R).

Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R).

Journal: HemaSphere

Published: September 08, 2025

End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.

End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.

Journal: European journal of nuclear medicine and molecular imaging

Published: December 27, 2023

Delayed cold-type autoimmune hemolytic anemia responding to Rituximab in a melanoma patient treated with Ipilimumab and Nivolumab.

Delayed cold-type autoimmune hemolytic anemia responding to Rituximab in a melanoma patient treated with Ipilimumab and Nivolumab.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 20, 2023

Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients.

Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients.

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Published: February 07, 2023

The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.

The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.

Journal: Frontiers in pharmacology

Published: April 28, 2017

Are ongoing trials on hematologic malignancies still excluding older subjects?

Are ongoing trials on hematologic malignancies still excluding older subjects?

Journal: Haematologica

Published: July 02, 2013

IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas.

IRTA1 is selectively expressed in nodal and extranodal marginal zone lymphomas.

Journal: Histopathology

Published: June 22, 2012

Reactivation of hepatitis B virus replication due to cytotoxic therapy: a five-year prospective study.

Reactivation of hepatitis B virus replication due to cytotoxic therapy: a five-year prospective study.

Journal: Tumori

Published: June 09, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026